New combo therapy aims to improve first-line lymphoma treatment
NCT ID NCT04792502
First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 21 times
Summary
This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants receive the drugs in cycles, with adjustments based on how well the cancer responds. The goal is to see how many people achieve complete remission. The study is currently recruiting 52 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lifespan Cancer Insitute
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
NOT_YET_RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.